Healthcare provider profile · identity verified

Yuping Chen, MD

Allopathic & Osteopathic Physicians|General Practice · FLUSHING, NY · NPI 1801986500

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Yuping Chen, MD received $30.00 in general payments during 2025 across 1 reported records.

Gilead Sciences, Inc. accounted for 100.0% of that reported general-payment amount.

Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Vemlidy by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$30.00

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Gilead Sciences, Inc.	Unresolved — no canonical attribution shown	$30.00	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$30.00	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Gilead Sciences, Inc. Exact reporting entity; no affiliate inference	2025	Vemlidy open payments reported associated product	CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906	Vemlidy · 2024 Exact normalized brand match · 1 Part D row	57	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1289	308
Losartan Potassium	Losartan Potassium	892	219
Amlodipine Besylate	Amlodipine Besylate	879	206
Raloxifene Hcl	Raloxifene Hcl	473	100
Rosuvastatin Calcium	Rosuvastatin Calcium	473	101
Glipizide Er	Glipizide	396	79
Metformin Hcl Er	Metformin Hcl	357	77
Omeprazole	Omeprazole	347	127
Tamsulosin Hcl	Tamsulosin Hcl	330	86
Levothyroxine Sodium	Levothyroxine Sodium	317	68
Alendronate Sodium	Alendronate Sodium	262	82
Metoprolol Succinate	Metoprolol Succinate	234	62
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	210	42
Atenolol	Atenolol	207	45
Nifedipine Er	Nifedipine	177	34
Famotidine	Famotidine	164	49
Metformin Hcl	Metformin Hcl	164	51
Meloxicam	Meloxicam	161	101
Diclofenac Epolamine	Diclofenac Epolamine	154	53
Clopidogrel	Clopidogrel Bisulfate	152	35
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	147	146
Gabapentin	Gabapentin	144	56
Pioglitazone Hcl	Pioglitazone Hcl	140	30
Vascepa	Icosapent Ethyl	134	30
Finasteride	Finasteride	130	36
Zolpidem Tartrate	Zolpidem Tartrate	128	51
Jardiance	Empagliflozin	124	22
Fluticasone Propionate	Fluticasone Propionate	111	59
Azithromycin	Azithromycin	106	91
Farxiga	Dapagliflozin Propanediol	105	25
Mometasone Furoate	Mometasone Furoate	95	62
Alcohol Prep Pads	Alcohol Antiseptic Pads	87	36
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	79	14
Esomeprazole Magnesium	Esomeprazole Magnesium	77	22
Potassium Chloride	Potassium Chloride	76	18
Ammonium Lactate	Ammonium Lactate	73	44
Hydrochlorothiazide	Hydrochlorothiazide	71	19
Simvastatin	Simvastatin	71	24
Montelukast Sodium	Montelukast Sodium	70	16
Triamcinolone Acetonide	Triamcinolone Acetonide	69	54
Eliquis	Apixaban	67	18
Valsartan	Valsartan	67	14
Candesartan Cilexetil	Candesartan Cilexetil	66	11
Diclofenac Sodium	Diclofenac Sodium	61	41
Donepezil Hcl	Donepezil Hcl	60	18
Hydrocortisone	Hydrocortisone	59	39
Metoprolol Tartrate	Metoprolol Tartrate	59	15
Meclizine Hcl	Meclizine Hcl	58	43
Shingrix	Varicella-Zoster Ge/As01b/Pf	58	35
Xarelto	Rivaroxaban	58	12
Vemlidy	Tenofovir Alafenamide	57	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	56	22
Clonazepam	Clonazepam	55	15
Lisinopril	Lisinopril	49	11
Ibandronate Sodium	Ibandronate Sodium	48	13
Alcohol Pads	Alcohol Antiseptic Pads	47	20
Januvia	Sitagliptin Phosphate	47	suppressed
Ketoconazole	Ketoconazole	47	23
Olmesartan Medoxomil	Olmesartan Medoxomil	47	suppressed
Carvedilol	Carvedilol	46	13
Mirtazapine	Mirtazapine	45	19
Glipizide-Metformin	Glipizide/Metformin Hcl	44	13
Nortriptyline Hcl	Nortriptyline Hcl	44	14
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	43	12
Allopurinol	Allopurinol	42	suppressed
Synjardy	Empagliflozin/Metformin Hcl	39	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	36	33
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	36	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	35	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Azelastine Hcl	Azelastine Hcl	33	18
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	33	suppressed
Ezetimibe	Ezetimibe	32	suppressed
Tenofovir Disoproxil Fumarate	Tenofovir Disoproxil Fumarate	32	11
Glipizide	Glipizide	31	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	31	suppressed
Trazodone Hcl	Trazodone Hcl	30	17
Fenofibrate	Fenofibrate Nanocrystallized	29	suppressed
Febuxostat	Febuxostat	28	suppressed
Fenofibrate	Fenofibrate,micronized	28	suppressed
Furosemide	Furosemide	28	11
Halobetasol Propionate	Halobetasol Propionate	28	suppressed
Hydralazine Hcl	Hydralazine Hcl	28	suppressed
Mupirocin	Mupirocin	27	20
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	27	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	26	suppressed
Myrbetriq	Mirabegron	26	suppressed
Alprazolam	Alprazolam	25	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	25	18
Entresto	Sacubitril/Valsartan	25	suppressed
Icosapent Ethyl	Icosapent Ethyl	25	12
Celecoxib	Celecoxib	24	suppressed
Fluocinonide	Fluocinonide	23	12
Janumet	Sitagliptin Phos/Metformin Hcl	23	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Dapagliflozin	Dapagliflozin Propanediol	21	suppressed
Memantine Hcl	Memantine Hcl	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	21	suppressed
Enalapril Maleate	Enalapril Maleate	20	suppressed
Folic Acid	Folic Acid	20	suppressed
Glimepiride	Glimepiride	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Procto-Med Hc	Hydrocortisone	20	12
Albuterol Sulfate Hfa	Albuterol Sulfate	19	13
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	17	suppressed
Clotrimazole	Clotrimazole	17	suppressed
Creon	Lipase/Protease/Amylase	17	suppressed
Lansoprazole	Lansoprazole	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Ranolazine Er	Ranolazine	16	suppressed
Rybelsus	Semaglutide	16	suppressed
Incruse Ellipta	Umeclidinium Bromide	15	suppressed
Prolia	Denosumab	15	suppressed
Rivastigmine	Rivastigmine Tartrate	15	suppressed
Amoxicillin	Amoxicillin	14	13
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	14	suppressed
Cilostazol	Cilostazol	14	suppressed
Colchicine	Colchicine	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Multaq	Dronedarone Hcl	14	suppressed
Colesevelam Hcl	Colesevelam Hcl	13	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	13	suppressed
Labetalol Hcl	Labetalol Hcl	13	suppressed
Pro Comfort Alcohol Pads	Alcohol Antiseptic Pads	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	13	11
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	12	suppressed
Torsemide	Torsemide	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	11	11
Ciclopirox	Ciclopirox	11	suppressed
Ibuprofen	Ibuprofen	11	11
Irbesartan	Irbesartan	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed
Zenpep	Lipase/Protease/Amylase	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$30.00 · 1 records	Gilead Sciences, Inc.	—	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error